TriangleDISEASE & TREATMENT SETTING
Bile Duct Cancer (Cholangiocarcinoma)
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Bile Duct Cancer (Cholangiocarcinoma)
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Bile Duct Cancer (Cholangiocarcinoma). Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
5 more-specific settings
Lytgobi: unresectable metastatic Cholangiocarcinoma with FGFR2 stated without a specific alteration →Pemazyre: unresectable metastatic Cholangiocarcinoma with FGFR2 stated without a specific alteration →Truseltiq: unresectable metastatic Cholangiocarcinoma with FGFR2 stated without a specific alteration →localized Bile Duct Cancer (Cholangiocarcinoma) →recurrent Bile Duct Cancer (Cholangiocarcinoma) →
Study evidence for this setting
Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
A Study of TAS-120 in Patients With Advanced Solid Tumors
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Fam
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expres
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Milademetan in Advanced/Metastatic Solid Tumors
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Indication-specific source history
2020-04-17 · Pemazyre (pemigatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-bile-duct-cancer-cholangiocarcinoma
- event id
- fda-e5ad133d33cdab21
- event date
- 2020-04-17
- event kind
- accelerated-approval
- drug or regimen
- Pemazyre (pemigatinib)
- source indication text
- Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
- match phrase
- cholangiocarcinoma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-4923a44876544e9cc7af
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-05-28 · Truseltiq (infigratinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-bile-duct-cancer-cholangiocarcinoma
- event id
- fda-3b91cae45e28a7a7
- event date
- 2021-05-28
- event kind
- accelerated-approval
- drug or regimen
- Truseltiq (infigratinib)
- source indication text
- Treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangement as detected by an FDA approved test
- match phrase
- cholangiocarcinoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-4da7c2b207d7377cc7db
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2022-09-30 · Lytgobi (futibatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-bile-duct-cancer-cholangiocarcinoma
- event id
- fda-80ee2df7a7edb38e
- event date
- 2022-09-30
- event kind
- accelerated-approval
- drug or regimen
- Lytgobi (futibatinib)
- source indication text
- Adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
- match phrase
- cholangiocarcinoma
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-76b547165392fa30999c
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-05-16 · Truseltiq (infigratinib) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-bile-duct-cancer-cholangiocarcinoma
- event id
- fda-5b2d8b60f1b2d489
- event date
- 2024-05-16
- event kind
- withdrawal
- drug or regimen
- Truseltiq (infigratinib)
- source indication text
- Treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangement as detected by an FDA approved test
- match phrase
- cholangiocarcinoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-4da7c2b207d7377cc7db
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-08 · zenocutuzumab-zbco · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-bile-duct-cancer-cholangiocarcinoma
- event id
- notice-7b382c5cf9fd0248
- event date
- 2026-05-08
- event kind
- approval-notification
- drug or regimen
- zenocutuzumab-zbco
- source indication text
- FDA approved zenocutuzumab-zbco for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
- match phrase
- cholangiocarcinoma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-da34fd1212e64f9b
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-bile-duct-cancer-cholangiocarcinoma
- binding id
- ncit-C227650
- source collection
- ncit-concept
- source key
- C227650
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-bile-duct-cancer-cholangiocarcinoma
- binding id
- ncit-C4436
- source collection
- ncit-concept
- source key
- C4436
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice